Commerzbank Aktiengesellschaft FI grew its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 8.4% in the third quarter, according to its most recent filing with the SEC. The firm owned 21,381 shares of the medical research company’s stock after acquiring an additional 1,657 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Edwards Lifesciences were worth $2,337,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in EW. Bank of New York Mellon Corp raised its stake in shares of Edwards Lifesciences by 161.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock worth $627,207,000 after buying an additional 3,277,726 shares in the last quarter. Koch Industries Inc. raised its stake in shares of Edwards Lifesciences by 28,363.1% in the 2nd quarter. Koch Industries Inc. now owns 1,397,254 shares of the medical research company’s stock worth $1,386,000 after buying an additional 1,392,345 shares in the last quarter. Artisan Partners Limited Partnership raised its stake in shares of Edwards Lifesciences by 90.6% in the 2nd quarter. Artisan Partners Limited Partnership now owns 1,278,532 shares of the medical research company’s stock worth $151,174,000 after buying an additional 607,784 shares in the last quarter. Old Mutual Global Investors UK Ltd. raised its stake in shares of Edwards Lifesciences by 83.0% in the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 1,100,885 shares of the medical research company’s stock worth $120,337,000 after buying an additional 499,436 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Edwards Lifesciences by 20.2% in the 3rd quarter. Wells Fargo & Company MN now owns 2,548,282 shares of the medical research company’s stock worth $278,553,000 after buying an additional 429,022 shares in the last quarter. Institutional investors own 81.63% of the company’s stock.

A number of analysts have recently commented on EW shares. Canaccord Genuity reissued a “buy” rating and issued a $135.00 price objective (down previously from $155.00) on shares of Edwards Lifesciences in a research note on Wednesday, October 25th. BMO Capital Markets reissued a “buy” rating and issued a $132.00 price objective on shares of Edwards Lifesciences in a research note on Friday, September 1st. William Blair reissued an “outperform” rating on shares of Edwards Lifesciences in a research note on Monday, August 28th. SunTrust Banks set a $124.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Finally, Morgan Stanley dropped their price objective on Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating on the stock in a research note on Thursday, October 26th. Seven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $125.53.

In related news, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $112.45, for a total transaction of $3,699,605.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $116.45, for a total value of $617,185.00. The disclosure for this sale can be found here. Insiders have sold 172,480 shares of company stock worth $18,548,810 over the last three months. 2.13% of the stock is owned by insiders.

Shares of Edwards Lifesciences Corporation (EW) traded up $0.59 during trading on Wednesday, hitting $113.64. The stock had a trading volume of 463,973 shares, compared to its average volume of 1,641,731. The firm has a market capitalization of $24,082.35, a price-to-earnings ratio of 31.52, a PEG ratio of 2.04 and a beta of 0.51. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33. Edwards Lifesciences Corporation has a 12 month low of $81.85 and a 12 month high of $121.45.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). The company had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. Edwards Lifesciences had a return on equity of 27.22% and a net margin of 22.47%. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period last year, the firm earned $0.68 earnings per share. equities analysts anticipate that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://theolympiareport.com/2017/12/06/commerzbank-aktiengesellschaft-fi-has-2-34-million-holdings-in-edwards-lifesciences-corporation-ew.html.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.